Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda    

January 21, 2021 11:51 PM UTC

Preclinical protein degradation play Plexium Inc. raised $35 million in an extension of its series A round and appointed Mike Grey as chairman. The financing, led by Lux Capital and Pivotal BioVentures, brings the A round to $63 million. Existing investors Column Group and DCVC Bio also participated. Grey is a venture partner at Pappas Ventures; executive chairman of Amplyx Pharmaceuticals Inc., Reneo Pharmaceuticals Inc. and Spruce Biosciences Inc. (NASDAQ:SPRB); and chairman of Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) in addition to holding other board seats.

Immunotech gains China rights to renal cancer program
T-Cure Bioscience Inc. granted China rights to Immunotech Biopharm Ltd. (HKEX:6978) for 800TCR, a HERV-E targeting TCR therapy for renal cell cancer (RCC). Immunotech will make an upfront payment and T-Cure is eligible for milestone payments and tiered royalties. Financial terms were not disclosed. The TCR therapy is in a Phase I trial at National Heart Lung and Blood Institute to treat metastatic clear cell RCC that failed an angiogenic inhibitor and a checkpoint inhibitor...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article